3 ASX healthcare stocks soaring on positive company updates

These companies have exciting news for investors today.

| More on:
Three health professionals at a hospital smile for the camera.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX healthcare stocks are in the green on Friday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) 0.41% higher while the benchmark S&P/ASX 200 Index (ASX: XJO) is up 0.32%.

Here are three of the best-performing ASX healthcare shares and why they are rising on Friday.

3 ASX healthcare shares zooming higher on positive news

4DMedical Ltd (ASX: 4DX)

The 4DMedical share price is up 7.9% at 61 cents per share at the time of writing.

The respiratory imaging technology company's shares are lifting on news of a commercial agreement with Qscan Radiology Clinics (QScan).

The contract follows a successful pilot of 4DMedical's products with Qscan, which is a leading provider of diagnostic imaging services in Queensland.

Under the deal, Qscan will offer 4DMedical's respiratory imaging solutions at select practices in Brisbane.

This is the first Australian contract for 4DMedical that incorporates products from both its pulmonary function and pulmonary structure suites, including CT LVAS.

4DMedical CEO and founder Andreas Fouras said:

Momentum continues to build with the commercialisation of our technology across the US and Australia.

Paradigm Biopharmaceuticals Ltd (ASX: PAR)

The Paradigm Biopharmaceuticals share price is 5.7% higher at 47 cents per share.

Paradigm is an ASX biotech that is focused on repurposing Pentosan Polysulfate Sodium (PPS) for the treatment of knee osteoarthritis.

The company announced today that it has received a $6,300,438 research and development (R&D) tax incentive refund from the Australian Government for the 2024 financial year.

This raises the company's current cash balance to approximately $31 million.

Paradigm managing director Paul Rennie commented:

With our cash position further boosted with this incentive refund, we are well-positioned to progress our Phase 3 clinical trial activities and subject recruitment in Australia.

The R&D tax incentive program is designed to encourage innovation through R&D activities in
Australia. Eligible companies can receive refundable cash offsets of 43.5% for qualifying R&D costs.

Somnomed Ltd (ASX: SOM)

The Somnomed share price is 6.7% higher at 64 cents per share.

Somnomed designs and manufactures oral treatments for sleep-related breathing disorders and obstructive sleep apnea.

The company released its December quarter activities report and FY25 guidance update today.

Somnomed reported 2Q FY25 revenue of $28.5 million, up 19.8% on the prior corresponding period (pcp).

Net cash inflow from operating activities was positive at $1.5 million.

The cash balance at the end of the quarter was $18.5 million, with a $1 million unsecured loan facility in Europe fully drawn.

For FY25, the company now expects revenue of approximately $105 million and earnings before interest, taxes, depreciation, and amortisation (EBITDA) of between $7 million and $9 million.

It expects capex costs of between $3 million to $4 million.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »